Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor
cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of
docetaxel by making the tumor cells more sensitive to the drug. It is not yet known if
docetaxel is more effective with or without oblimersen in treating non-small cell lung
cancer.
PURPOSE: Randomized phase II/III trial to compare the effectiveness of docetaxel with or
without oblimersen in treating patients who have relapsed or refractory non-small cell lung
cancer that has been previously treated.